
Opinion|Videos|June 12, 2024
Addressing Unmet Needs in the PAH Landscape
Author(s)Marius Hoeper, MD
Marius Hoeper, MD, describes the role clinicians can play in advocating for health care system reforms that could address the economic implications of PAH and discusses the key unmet needs in the PAH treatment landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What role can clinicians play in advocating for integrated care delivery models, value-based payment strategies, or other health care system reforms that could address the economic implications of pulmonary arterial hypertension (PAH) more effectively?
- What are the key unmet needs or challenges related to the management of PAH that you hope will be addressed more comprehensively in the coming years as the treatment landscape evolves with therapies like sotatercept?
Advertisement
Related to this article

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5



